The MedTech snapshot: Why “assurance” became the growth strategy in 2025

The last 12 months didn’t just add new rules and checklists, they rewired how MedTech gets bought. Across Europe and the US, procurement, regulatory, cybersecurity, data governance, and (increasingly) AI governance have converged into a single commercial gating function. The organisations gaining momentum aren’t merely shipping product; they’re shipping certainty: auditable safety, governed change, resilient supply, and buyer-ready evidence that survives security review, tender scrutiny, and contracting.

For manufacturers and suppliers, this is the new competitive surface area: the ability to operationalise trust at scale — without slowing innovation.

1) Europe’s compliance machinery moved from “event” to “operating model”

The most under appreciated MedTech shift is that compliance is now a continuous throughput problem. In 2025, the EU made this tangible with EUDAMED timelines: the European Commission confirmed that from 28 May 2026, four modules become mandatory (Actor registration, UDI/Devices registration, Notified Bodies & Certificates, and Market Surveillance).

That sounds administrative, but commercially it’s profound. It forces a move away from periodic “documentation pushes” toward durable capabilities: clean master data, traceability discipline, certificate visibility, and an always-on market surveillance posture. Manufacturers feel this as an internal operating transformation; suppliers feel it as a new expectation to provide structured, version-controlled inputs that can withstand audits and buyer scrutiny.

2) Cybersecurity stopped being a technical workstream and became a procurement qualifier

Security is now a primary driver of deal velocity, especially for connected devices, software-heavy platforms, and anything that touches enterprise networks or sensitive workflows.

In the US, FDA’s guidance on cybersecurity in medical devices (updated mid-2025) makes expectations explicit: cybersecurity needs to be designed into the device, reflected in labelling, and supported by documentation in premarket submissions.

In the EU, the compliance “tone” shifted as well. The NIS2 framework became the active reference point for many organisations, with Member States required to transpose it by 17 October 2024, and NIS2 repealing NIS1 from 18 October 2024. This matters to MedTech because enterprise buyers increasingly treat cybersecurity obligations as part of supplier eligibility — even when the legal target is an operator or essential entity. Put simply: if your customer must prove resilience, they will demand it from you.

Commercial reality: security review is often the hidden critical path. If you cannot respond quickly and consistently on SBOM posture, vulnerability handling SLAs, patch governance, logging/auditability, and incident response boundaries, procurement will delay, de-risk by choosing incumbents, or price-pressure to offset perceived exposure.

3) AI matured from “innovation narrative” to “governed change”

The AI story in 2025 became less about whether you use AI, and more about whether you can govern it. In Europe, the EU AI Act’s timeline moved into practical obligations: prohibited practices and AI literacy obligations applied from 2 February 2025, and governance rules/obligations for general-purpose AI models from 2 August 2025.

In the US, FDA’s PCCP guidance (published 18 August 2025) sharpened a core theme for AI-enabled device software functions: define in advance what will change, how it will be validated, and how impact will be assessed — so improvements can be deployed without re-filing for every iteration.

For manufacturers, this is an engineering and quality-system design requirement. For suppliers, it is a partnership requirement: OEMs increasingly need upstream partners who can support the OEM’s governance story with evidence, controls, and predictable change mechanisms.

4) Data rights became a front-line commercial term for connected MedTech

The EU Data Act became applicable on 12 September 2025. For connected devices and related services, this is not theoretical, it reframes how access to device-generated data, portability, and sharing are handled. It also elevates interoperability and exportability from “integration nice-to-have” to a commercial pressure point.

Commercial consequence: data governance is now negotiated like pricing. Buyers want optionality (avoid lock-in), proof of control (auditability), and clarity on who can access what, where, and under which security and contractual constraints. The winners will be those who can present data flows, access controls, retention/deletion, sub-processor visibility, and export formats in procurement-ready terms — with minimal back-and-forth.

5) Procurement hardened: value, resilience, and geopolitics now shape eligibility

Procurement is becoming more strategic, more outcomes-oriented, and more explicit about risk. In the UK, NHS Supply Chain launched new Value Based Procurement (VBP) guidelines on 17 October 2025, reinforcing the move from unit price to measurable value and broader decision domains.

Separately, geopolitics reached the tender gate. On 19 June 2025, the European Commission adopted a measure under the International Procurement Instrument restricting Chinese participation in EU public procurement of medical devices above €5 million (with guardrails around subcontracting and origin content). This type of eligibility constraint doesn’t just affect China-linked bidders — it forces every bidder to understand and evidence supply-chain provenance and subcontracting composition with greater precision.

6) The payer/utilisation layer tightened and MedTech demand will increasingly feel it

In the US, CMS announced a five-year prior authorisation demonstration for certain ASC services beginning 15 December 2025 across 10 states, before later delaying and phasing start dates into early 2026 (without changing the underlying direction of travel).

For MedTech, this is a reminder that adoption curves are not only clinical and operational — they’re also administrative. Even when a device is valuable, the surrounding policy mechanics can add friction that procurement teams will try to anticipate and manage.

So what’s the unifying pattern?

Across all of the above, one theme dominates: buyers are institutionalising risk control. They are doing it through procurement frameworks, security reviews, contract clauses, and lifecycle evidence expectations. That’s why the organisations winning disproportionately in 2025 are building what can be called a procurement-aligned assurance stack: a single, buyer-consumable system of proof that maps directly to procurement’s decision points (vendor onboarding → tender evaluation → security review → contracting → post-award governance).

For manufacturers, the stack is how you scale trust across markets and accounts without slowing sales. For suppliers, the stack is how you become “pull-through” in OEM bids by reducing the OEM’s burden and uncertainty.

Conclusion: the 2026 winners will be the ones who operationalise trust

If 2024 was about GenAI excitement and regulatory transition talk, 2025 was the year MedTech buyers started enforcing governability. In 2026, the advantage will compound for organisations that treat assurance as a product discipline: version-controlled evidence libraries, clear change governance (especially for software and AI), fast security review responses, and procurement-native narratives that quantify value while de-risking adoption.

The immediate opportunity is straightforward: align cross-functional stakeholders (RA/QA, Security, Product, Clinical, Legal, Commercial) around a shared “assurance spine,” and make it reusable. The organisations that do this will shorten cycles, protect pricing, and expand faster, not because they avoid complexity, but because they’ve learned to package it into certainty that procurement can approve at speed.